CSIMarket Company Name, Ticker, Competitors, else..
 
Mesoblast Limited  (NASDAQ: MESO)
 
Price: $15.4400 $-0.06 -0.387%
Day's High: $15.649999618530273 Week Perf: -10.85 %
Day's Low: $ 15.43 30 Day Perf: -7.99 %
Volume (M): 71,237 52 Wk High: $ 21.50
Volume (M$): $ 0 52 Wk Avg: $16.20
Open: $15.57 52 Wk Low: $13.05



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 108
 Revenues (TTM) (Millions $) 17
 Net Income (TTM) (Millions $) -102
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 1

Business Description


Mesoblast Ltd is an Australian-based regenerative medicine company that focuses on developing and commercializing cell-based therapies. The company specializes in utilizing their proprietary technology platform to develop novel treatments for a wide range of diseases including cardiovascular conditions, orthopedic disorders, and immunologic disorders. Mesoblast's therapies are based on the use of mesenchymal precursor cells, which have the ability to differentiate into various cell types and promote tissue repair and regeneration. The company has several products in various stages of clinical development, and they collaborate with pharmaceutical partners for the commercialization of their therapies.


   Company Address: Level 38 Melbourne 3000
   Company Phone Number: 9639 6036   Stock Exchange / Ticker: NASDAQ MESO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -14.71%    
BCRX   -18.73%    
BIIB   -3.85%    
EXEL   -4.87%    
GILD   -4.38%    
IOVA   -6.38%    
• View Complete Report
   



Clinical Study

Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation

Published Wed, Nov 5 2025 10:30 AM UTC

Pioneering Discussions: Mesoblast Poised for FDA Meeting on Rexlemestrocel-L and Opioid CessationIn a significant step towards revolutionising pain management, Mesoblast Limited (Nasdaq: MESO; ASX: MSB), a global frontrunner in allogeneic cellular medicines for inflammatory diseases, has announced its upcoming meeting with the U.S. Food and Drug Administration (FDA) schedul...
Product Service News

for the Mesoblast Secures U.S. Origin Designation for Cell Therapies Amidst Industry Headwinds Strategic A...

Published Fri, Sep 26 2025 9:35 AM UTC

Mesoblast Achieves Strategic Milestone: Cell Therapy Products Secure U.S. Origin Designation Amidst Industry Challenges Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a pioneering force in the development of allogeneic cellular medicines for inflammatory diseases, has made a significant announcement confirming that its allogeneic cell therapy products are manufactured from U.S. d...
Product Service News

Expanding Horizons Mesoblasts Ryoncil Gains Extensive Coverage Amidst Financial Challenges

Published Thu, Apr 17 2025 5:48 AM UTC

: In a noteworthy advancement for the field of regenerative medicine, Mesoblast Ltd has expanded payer coverage for its pioneering therapy, Ryoncil (remestemcel-L), to over 104 million U.S. lives. Despite this significant milestone, Mesoblast faces a challenging financial landscape, as evidenced by a marked decline in revenue in comparison to its competitors. This article d...
Stock Market Announcement

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor in Ischemic Heart Failure

Published Wed, Apr 2 2025 11:15 PM UTC

Mesoblast Advances Plans for Revascor in Ischemic Heart Failure: Exploring Accelerated Approval with FDAIn a significant development for the biopharmaceutical sector, Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, has announced its intent to engage with the United States Food and Drug Administration (FDA...
Product Service News

Mesoblast Allogeneic Cell Therapy Products Are Designated U.S. Country of Origin and Not Subject to U.S. Tariffs

Published Fri, Apr 4 2025 12:59 AM UTC

Mesoblast s Strategic Advancement: U.S. Tariff Exemption and Medical Designations Propel Innovative Cell Therapies New York, April 03, 2025 In a dual win for Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global frontrunner in the advancement of allogeneic cellular medicines for inflammatory diseases, significant strides have been made concerning the company s flagship prod...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.9
Working Capital Ratio 2.82
Leverage Ratio (MRQ) 0.36
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 0 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash -
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 159,241
Net Income per Employee (TTM) -945,759
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.02

Profitability Ratios Current
Gross Margin (MRQ) 70.17 %
Operating Margin (MRQ) -429.6 %
Net Margin (MRQ) -593.92 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Mesoblast Limited's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.